Literature DB >> 11018082

Response rates, survival, and chemotherapy trials.

R Pazdur.   

Abstract

Mesh：

Year:  2000        PMID： 11018082     DOI： 10.1093/jnci/92.19.1552

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.

Authors:  Rajul K Jain; J Jack Lee; Chaan Ng; David Hong; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

2.  Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial.

Authors:  Atis Muehlenbachs; Carolyn Nabasumba; Rose McGready; Eleanor Turyakira; Benon Tumwebaze; Mehul Dhorda; Dan Nyehangane; Aisha Nalusaji; Franois Nosten; Philippe J Guerin; Patrice Piola
Journal:  Malar J       Date:  2012-05-03       Impact factor: 2.979

3.  Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

Authors:  Nathan R Foster; Yingwei Qi; Qian Shi; James E Krook; John W Kugler; James R Jett; Julian R Molina; Steven E Schild; Alex A Adjei; Sumithra J Mandrekar
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

Review 4.  MR Imaging Biomarkers in Oncology Clinical Trials.

Authors:  Richard G Abramson; Lori R Arlinghaus; Adrienne N Dula; C Chad Quarles; Ashley M Stokes; Jared A Weis; Jennifer G Whisenant; Eduard Y Chekmenev; Igor Zhukov; Jason M Williams; Thomas E Yankeelov
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

5.  Do firms underinvest in long-term research? Evidence from cancer clinical trials.

Authors:  Eric Budish; Benjamin N Roin; Heidi Williams
Journal:  Am Econ Rev       Date:  2015-07

6.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Authors:  Charles Ferté; Marianna Fernandez; Antoine Hollebecque; Serge Koscielny; Antonin Levy; Christophe Massard; Rastislav Balheda; Brian Bot; Carlos Gomez-Roca; Clarisse Dromain; Samy Ammari; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

7.  Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network.

Authors:  Yan Zhang; Xin Li; Dianshuang Zhou; Hui Zhi; Peng Wang; Yue Gao; Maoni Guo; Ming Yue; Yanxia Wang; Weitao Shen; Shangwei Ning; Yixue Li; Xia Li
Journal:  Mol Oncol       Date:  2018-07-14       Impact factor: 6.603

Review 8.  Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.

Authors:  Giuseppe Aprile; Caterina Fontanella; Marta Bonotto; Karim Rihawi; Stefania Eufemia Lutrino; Laura Ferrari; Mariaelena Casagrande; Elena Ongaro; Massimiliano Berretta; Antonio Avallone; Gerardo Rosati; Francesco Giuliani; Gianpiero Fasola
Journal:  Oncotarget       Date:  2015-10-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.